Study: Florida’s tougher drug laws and monitoring program is positively impacting opioid prevention efforts.
Florida’s prescription drug monitoring program (PDMP) and pill mill laws have led to statistically significant decreases in opioid prescriptions, opioid volume and morphine milligram equivalent per transaction, according to a new study in JAMA Internal Medicine.
After the implementation of Florida’s stringent laws and PDMP:
These statistics illustrate the dramatic impact Florida’s PDMP and tougher laws have had on rogue pill mills, opioid abuse and overdose deaths, says Kent Runyon, executive director of Novus Medical Detox Center.
Related:Study: One in two teens misuse Rx drugs
“Other states would be wise to follow Florida’s example, since pain clinics will set up shop wherever there are lax laws and weak regulatory oversight,” Runyon says. “Everyone involved in direct patient care or in any way affiliated with medical care is impacted by persons suffering from addiction and abuse of prescription medications. This behavior increases the cost of care and counteracts any efforts put toward wellness.”
This system tracks prescription medication orders and therefore can lead to the identification of persons who are doctor shopping or by other means are filling prescriptions at a rate that suggests some form of abuse or illegal activity, according to Runyon.
NEXT: Information sharing among states
The programs, which indicate details such as when and where patients have controlled medications filled, could help prevent patients from getting controlled medications from multiple physicians-but current programs could also benefit from modernization, because while they already exist in most U.S. states, the level of information sharing among states is minimal.
“That gap is what allows those struggling with addiction to visit neighboring states and retain access to their drug of choice with no repercussions,” he says.
There are three things to remember, he says:
“When the pill mills were shutting down in Florida they began opening in Georgia where they did not have as laws as strong,” Runyon says. “The programs are not necessarily mandated or enforced in all states; and there are indications that some patients attempt to circumvent these programs by filling prescriptions out of state.”
Related:AMCP fights back: Abuse-deterrent opioid coverage mandate
An Express Scripts analysis found that “residents from seven neighboring states filled opiate prescriptions in Missouri as much as four times more often than residents in Missouri filled opioid prescriptions out of state.”
“While many physicians and pharmacists are cautious about issuing prescriptions that can lead to dependency or dangerous interactions, the current system has too many loopholes, which is why so many patients are able to access dangerous combinations of prescription drugs,” he says.
The bottom line is that systems must communicate, Runyon says.
“We cannot ever underestimate the desperate acts that will be taken to gain access to certain prescription medications,” he says. “We need to insure that while we are making it more difficult for people to get access to these prescription drugs that we also continue to make it easier for them to get the help that they need. But while many states are now pushing for databases that allow law enforcement agencies to track drug-related overdoses, deaths, hospital admissions and crimes, the true key to stemming the rise of prescription drug abuse is not by treating addicted individuals as criminals, but by understanding that they were once contributing members of society who now need help getting their lives back.”
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More